Heterosexually acquired human immunodeficiency virus infection and the United States blood supply: considerations for screening of potential blood donors. HIV Blood Donor Study Group.
The impact of heterosexual transmission of the human immunodeficiency virus (HIV) on the United States blood supply was assessed, and deferral criteria that may exclude potential donors who are at high risk for heterosexually acquired HIV infection were evaluated. Interviews were conducted with 508 HIV-seropositive blood donors from May 1, 1988, to August 31, 1989 (Phase 1), and with 472 donors from January 1, 1990, to May 31, 1991 (Phase 2), at 20 blood centers. From Phase 1 to Phase 2, the overall HIV prevalence decreased from 0.021 to 0.018 percent (p < 0.001). HIV risk factors among HIV-1-seropositive donors were similar during both study phases. Eleven percent of the men and 56 percent of the women reported as their only risk that they had a heterosexual partner who was at increased risk for HIV or was known to have HIV. These percentages were similar during both study periods. During Phase 2, 13 percent of the men and 17 percent of the women with heterosexual transmission risk had a positive serologic test for syphilis, hepatitis B core antibody, or hepatitis C antibody. Among HIV-1-seropositive donors reporting heterosexual risk, the median numbers of previous-year and lifetime sex partners for men were 2 and 30, respectively; for women, those numbers were 1 and 7, respectively. Thirty-one percent of the men and 6 percent of the women reporting heterosexual transmission risk also reported having had syphilis or gonorrhea within 3 years of donation. It is concluded that the impact of heterosexual transmission of HIV infection on transfusion safety is not worsening at this time.(ABSTRACT TRUNCATED AT 250 WORDS)
Petersen
L R
LR
Division of HIV/AIDS, National Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA.
Doll
L S
LS
White
C R
CR
Johnson
E
E
Williams
A
A
D001771:Blood Banks / Q000706:statistics & numerical data*; D002487:Centers for Disease Control and Prevention, U.S.; D005260:Female; D015658:HIV Infections / Q000453:epidemiology / Q000209:etiology*; D006679:HIV Seropositivity / Q000453:epidemiology / Q000635:transmission*; D015528:HIV Seroprevalence; D016174:Hepacivirus / Q000276:immunology; D006508:Hepatitis Antibodies / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000276:immunology; D018937:Hepatitis C Antibodies; D006801:Humans; D008297:Male; D012307:Risk Factors; D012725:Sexual Behavior; D013587:Syphilis / Q000175:diagnosis; D014019:Tissue Donors; D014481:United States / Q000453:epidemiology
D006508:Hepatitis Antibodies; D006512:Hepatitis B Core Antigens; D018937:Hepatitis C Antibodies